Posted by Michael Wonder on 06 Nov 2023
Expanded reimbursement for Spinraza improves patient access
2 November 2023 - Biogen Korea is strengthening its position in the local spinal muscular atrophy market with expanded reimbursement benefit of Spinraza (nusinersen), the company said Thursday.
Biogen Korea held a press conference on Thursday, to commemorate the expansion of the reimbursement criteria for Spinraza to include type 3 patients whose symptoms appear after three years old.
